Local and System Interferon Therapy in Treatment of Immunocompromisecl Patients with Allergic Rhinitis and Bronchial Asthma

摘要

Acute respiratory viral infections (ARVI) can provoke the development of respiratory allergic diseases exacerbations including allergic rhinitis (AR) and atopic bronchial asthma (BA). A program of local and systemic interferonotherapy was developed as an integrated part of combined treatment of immunocompromised patients with AR and BA who also suffer from recurrent viral bacterial respiratory infections. The aim of the program was to restore defects in the immune and interferon system and included selective beta_2 agonists combined with topic steroids; antihistamines; nasal irrigation; elimination regime for allergens and antigens; antioxidants; sanation of chronic niduses of infection; local and systemic interferon therapy with recombinant IFNalpha_2; immunomodulation on demand; restoration of mucosal microbiocenosis. The state of immune and interferon status and microbiocenosis of open and internal mucous was checked every two months. Positive effects of immunotropic therapy were registered in 74.72% patients after two months. AR and BA exacerbations were absent for 2.5-3 months, no episodes of ARVI and bacterial infection were registered during this period. In a year, the duration of remission increased 5.5-fold, the rate of ARVI decreased to one-to-two per a year, while the occurrence of ARVI complications decreased 3.9-fold. High clinical and immunologic efficiency of local and system interferon therapy as an integral part of combined therapy of immunocompromised patients with AR and BA on the background of viral bacterial infections was shown.